**17. References**


[9] Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55(3): 407-419.

134 Lipoproteins – Role in Health and Diseases

CV cardiovascular

sdLDL small dense LDL TC total cholesterol

HR Hazards Ratio

RR Relative Risk

**17. References** 

255(2): 188-205.

XXI(1): 11-21.

120: 1012-1025.

VLDL Very Low Density Lipoprotein IDL Intermediate Density Lipoprotein

hsCRP high sensitivity CRP (C-reactive protein)

apolipoprotein B. J Lipid Res 1988; 29:1461-1473.

evidence. J Intern Med 2006; 259: 493-519.

Metab Cardiovasc Dis 2007; 17: 565-571.

statin therapy treatment. Lancet 2003; 361: 777-780.

of prospective studies. J Intern Med. 2006; 259: 481-492.

[1] Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione D L, Reeve Jr JR, Young NL. Plasma very low density lipoproteins contain a single molecule of

[2] Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;

[3] Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the

[4] Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for

[5] Walldius G, Jungner I. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoprotein B and A-I – new risk factors and targets for therapy. Nutr

[6] Walldius G, Jungner I. ApoB, apoA-I, and the apoB/apoA-I ratio as predictors, markers, and factors for cardiovascular risk. The Fats of Life, LVDD/AACC. www.aacc.org. 2007;

[7] Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994;

[8] Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis

LDL Low Density Lipoprotein

HDL high density lipoprotein

IVUS intravascular ultrasound CIMT carotid intima media thickness CRI Cardiovascular Risk Index

NRI Net Reclassification Index MACE Major Coronary Events


[37] Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaeffer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clinical Chemistry 1996; 42: 515-523.

136 Lipoproteins – Role in Health and Diseases

[23] Scharnagl H, Nauck M, Wieland H, März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001; 39: 426-431. [24] Otvos JD. Why cholesterol measurements may be misleading about lipoprotein levels and cardiovascular disease risk – clinical implications of lipoprotein quantification

[25] van Deventer HE, Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, Nakajima K, Nakamura M, Shamburek RD, Vetrovec GW, Warnick GR, Remaley AT. Non–HDL Cholesterol Shows Improved Accuracy for Cardiovascular Risk Score Classification Compared to Direct or Calculated LDL Cholesterol in a Dyslipidemic Population.

[26] Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B: III. Comparability of apolipoprotein A-I values by use of International Reference

[27] Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non–High-Density Lipoprotein and Very-Low-Density Lipoprotein Cholesterol and Their Risk Predictive

[28] Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B: IV. Comparability of apolipoprotein B

[30] Zambon A, Brown BG, Deeb SS, Brunzell JD. Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease. J Intern Med 2006; 259: 473-

[31] Gatz M, Reynolds CA, Finkel D, Pedersen NL, Walters E. Dementia in Swedish Twins: Predicting Incident Cases. Behav Genet 2010; 40:768-75, DOI 10.1007/s10519-010-9407-4. [32] Vladimirova-Kitova LG, Deneva-Koicheva TI. Increased Intima-Media Thickness in Carriers of the LDL-Receptor Defective Gene versus Noncarriers with Newly Detected Asymptomatic Severe Hypercholesterolemia. Echocardiography 2011; 28: 223-234. [33] Middelberg RPS, Spector TD, Swaminathan R, Snieder H. Genetic and Environmental Influences on Lipids, Lipoproteins, and Apolipoproteins Effects of Menopause.

[34] Schmidt C, Fagerberg, B Wikstrand J, Hulthe J. ApoB/apoA–I ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men.

[35] Hoff HF. Apolipoprotein Localization in Human Cranial Arteries, Coronary Arteries,

[36] Fogelstrand P, Borén J. Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis; Review. Nutrition, Metabolism & Cardiovascular Diseases 2012;

values by use of International Reference Material. Clin Chem 1994; 40: 586-592. [29] Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and

Values in Coronary Heart Disease. Am J Cardiol 2006; 98: 1363-1368.

apolipoprotein B plasma levels. J Intern Med 2006; 259: 437-446.

Arterioscler Thromb Vasc Biol. 2002; 22: 1142-1147.

Atherosclerosis 2006; 189: 178-185.

and the Aorta. Stroke 1976; 7(4): 390-393.

using NMR spectroscopy. J Lab Med 2002; 26: 544-550.

Clinical Chemistry 2011; 57(3): 490-501.

Material. Clin Chem 1993; 39: 773-781.

480.

22: 1-7.


[63] Sniderman AD, St-Pierre A, Cantin B, Dagenais GR, Depre´s J-P, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003; 91: 1173-1177.

138 Lipoproteins – Role in Health and Diseases

[51] Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin

[52] Gotto AM, Whitney E, Stein EA et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477-484. [53] Gotto, AM Jr. Establishing the benefit of statins in low-to-moderate—risk primary prevention: The Air Force/Texas Coronary. Atherosclerosis Prevention Study

[54] Simes RJ, Marschner IC, Hunt D et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by

[55] van Lennep JE, Westerveld HT, van Lennep HWO, Zwinderman AH, Erkelens DW, van der Wall EE. Apolipoprotein concentrations during treatment and recurrent coronary

[56] Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009; 265: 275-287. [57] Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL-C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-

[58] Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, et al., on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-

[59] McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the

[60] Parish S, Peto R, Palmer A, Clarke R, Lewington S, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009; 30(17):

[62] Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A Meta-analysis of LDL-C, non-HDL-C, and apoB as markers of cardiovascular

2137-2146. First published online June 11, 2009,doi:10.1093/eurheartj/ ehp221. [61] Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, De Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P. Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KMS. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-

artery disease events. Arterioscler Thromb Vasc Biol 2000; 20: 2408-2413.

Survival Study (4S). Circulation 1998; 97: 1453-1460.

(AFCAPS/TexCAPS). Atherosclerosis Supplements 2007; 8: 3-8.

related risk of vascular disease. J Intern Med 2006; 259: 455-461.

INTERHEART study): a case-control study. Lancet 2008; 372: 224-233.

control study. Lancet 2004; 364: 937-952.

country panel. J Intern Med 2006; 259: 247-258.

risk. Circ Cardiovasc Qual Outcomes. 2011; 4: 337-345.

on-study lipid levels? Circulation 2002; 105: 1162-1169.


[88] Holme I, Aastveit AH, Jungner I, Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2008; 264: 30-38.

140 Lipoproteins – Role in Health and Diseases

doi:10.1093/eurjhf/hfp202.

doi:10.1093/eurjhf/hfn046.

J Clin Lab Res 1992; 21: 247-255.

International Congress Series, 2004; 1262: 203-206.

Fatal Myocardial Infarction? Am J Cardiol 2006; 97: 943-946.

1992; I (suppl 4): 35-42.

Thromb Vasc Biol 2002; 22: 1155-1161.

[76] Luc G, Bard J-M, Ferrie`res J et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study.Prospective Epidemiological Study of Myocardial Infarction. Arterioscler

[77] Patel JV, Abraheem A, Creamer J, Gunning M, Hughes EA, Lip GYH. Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease. European Journal of Heart Failure 2010; 12: 254-259.

[78] Wedel H, McMurray JJV, Lindberg M, Wikstrand J, Cleland JGF, Cornel JH, Dunselman P, Hjalmarson Å, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F on behalf of the CORONA Study Group. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro Btype natriuretic peptide. European J Heart Fail 2009; 11: 281-291

[79] Chien K-L, Sung F-C, Hsu H-C, Su T-C, Lin R-S, Lee Y-T. Apolipoprotein A-I and B and Stroke Events in a Community-Based Cohort in Taiwan. Report of the Chin-Shan

[80] Van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ESG, Sandhu MS, Wareham NJ, J. Jukema JW, Luben R, Zwinderman AH, Kastelein JJP, Khaw K-T. Role of the Apolipoprotein B–Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment:

[83] Walldius G, Jungner I, Kolar W, Steiner E. Apolipoprotein B and total serum cholesterol

[84] Jungner I, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-1 in relation to serum cholesterol and triglycerides in 43,000 Swedish males and females. Int

[85] Walldius G, Jungner I, Kolar W, Holme I, Steiner E. High cholesterol and triglyceride values in Swedish males and females: increased risk of fatal myocardial infarction: First report from the AMORIS (Apolipoprotein related MOrtality RISk) Study. Blood Press

[86] Walldius G, Aastveit A, Jungner I. Hypercholesterolemia and hypertriglyceridemia greatest cardiac risk in subjects with high apoB/apoA-I levels. Original Research Article.

[87] Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G. Does Low-Density Lipoprotein Size Add to Atherogenic Particle Number in Predicting the Risk of

A Case–Control Analysis in EPIC-Norfolk. Ann Intern Med. 2007; 146: 640-648. [81] Walldius G, Jungner I. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol 2007; 22: 359-367. [82] Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization – International Federation of Clinical Chemistry First

Community Cardiovascular Study. Stroke. 2002; 33: 39-44.

International Reference Materials. Clin Chem 1998; 44: 1641-1649.

levels in 41 000 males and females. Clin Chem 1990; 36(6): 952-956.


Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009; 265: 275-287. doi: 10.1111/j.1365-2796.2008.02016.xJ.


[112] Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005; 26: 271-278.

142 Lipoproteins – Role in Health and Diseases

581-590.

10.1111/j.1365-2796.2008.02016.xJ.

10.1007/s00125-010-1871-0.

2007; 115: 1067-1074.

3554-3561.

3046.

Guidelines. Circulation. 2007; 115: 1075-1081.

Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009; 265: 275-287. doi:

[102] McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A, Prabhakaran D, Almahmeed W,Rumboldt Z, Budaj A, Dans AL, Gerstein HC, Teo K, Anand SS on behalf of the INTERHEART Investigators Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. European Heart Journal Advance Access published December 22, 2010. European Heart Journal, doi:10.1093/eurheartj/ehq448. Published in European Heart Journal 2011; 32:

[103] Gerstein HC, Islam S, Anand S, Almahmeed A, Damasceno A, Dans A, Lang CC, Luna MA, McQueen M, Rangarajan S, Rosengren A, Wang X, Yusuf S. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia 2010; 53: 2509-2517, DOI

[104] Joshi P, Islam S , Pais P, Reddy S, Dorairaj P, Kazmi K, Pandey MR, Haque S, Mendis S, Rangarajan S, Yusuf S. Risk Factors for Early Myocardial Infarction in South Asians

[105] Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, Yusuf S for the INTERHEART Investigators in Latin America. Risk Factors for Acute Myocardial Infarction in Latin America. The INTERHEART Latin American Study. Circulation

[106] Kabagambe EK, Baylin A, Campos H. Nonfatal Acute Myocardial Infarction in Costa Rica. Modifiable Risk Factors, Population-Attributable Risks, and Adherence to Dietary

[107] Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, Damasceno A, Ounpuu S, Yusuf S for the INTERHEART Investigators in Africa. Risk Factors Associated With Myocardial Infarction in Africa The INTERHEART Africa Study. Circulation 2005; 112:

[108] O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, qul Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S on behalf of the INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Published Online June 18, 2010

[109] Kostapanos MS, Christogiannis LG, Bika E, Bairaktari ET, Goudevenos JA, Elisaf MS, Milionis HJ. Apolipoprotein B-to-A1 Ratio as a Predictor of Acute Ischemic Nonembolic

[110] Park J-H, Hong K-S, Lee E-J, Lee J, Kim D-E. High Levels of Apolipoprotein B/AI Ratio Are Associated With Intracranial Atherosclerotic Stenosis. Stroke 2011; 42: 3040-

[111] Boekholdt SM, van der Steeg WA, Stein EA et al. The ratio of apolipoproteins B to A-I and the risk of future coronary artery disease in apparently healthy men and women; the EPIC-Norfolk prospective population study. Ann Intern Med. 2007; 146: 640-648.

DOI:10.1016/S0140- 6736(10)60834-3. Published in Lancet 2010; 376: 112–23.

Stroke in Elderly Subjects. J Stroke Cerebrovasc Dis. 2010; 19: 497-502.

Compared With Individuals in Other Countries. JAMA 2007; 297: 286-294.


[140] Enkhma B, Anuurad E, Zhanga Z, Pearson TA, Berglund L. Usefulness of Apolipoprotein B/Apolipoprotein A-I Ratio to Predict Coronary Artery Disease Independent of the Metabolic Syndrome in African Americans. Am J Cardiol 2010; 106: 1264-1269.

144 Lipoproteins – Role in Health and Diseases

[125] Stewart MW, Humphriss DB, Mitcheson J, Webster J, Walker M, Laker MF. Lipoprotein composition and serum apolipoproteins in normoglycaemic first-degree relatives of noninsulin dependent diabetic patients. Atherosclerosis 1998; 139: 115-121. [126] Kim BJ, Hwang ST, Sung KC et al. Comparison of the relationships between serum apolipoprotein B and serum lipid distributions. Clin Chem 2005; 51: 2257-2263. [127] Sung K.-C., Rhee E.-J., Kim H., Park, J.-B., Kim, Y.-K., Woo, S. Wilson A.M. An elevated apolipoprotein B/AI ratio is independently associated with microalbuminuria

[128] Kim H-K, Chang S-A, Choi E-K et al. Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk

[129] Snehalatha C, Ramachandran A, Sivasankari S et al. Is increased apolipoprotein B-A major factor enhancing the risk of coronary artery disease in type 2 diabetes? J Assoc

[130] Solymoss BC, Bourassa MG, Campeau L et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity.

[131] Lind L, Vessby B, Sundström J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men.

[132] Sierra-Johnson J, Romero-Corral A, Somers VK., Lopez-Jimenez F, Wall¬dius G, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic

[133] Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Öhrvik J, Walldius G, Hellenius ML, Hamsten A. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings

[134] Zhong L, Li Q, Jiang Y, Cheng D, Liu Z, Wang B, Luo R, Cheng Q, Qing H. The ApoB/ApoA1 Ratio is Associated with Metabolic Syndrome and its Components in a Chinese Population. Inflammation 2010; 33(6): 353-358. DOI:10.1007/s10753-010-9193-4. [135] Belfki H , Ben Ali S , Bougatef S, Ben Ahmed D, Haddad N , Jmal A, Abdennebi M , Ben Romdhane H. The Apolipoprotein B/Apolipoprotein A 1 ratio in relation to metabolic syndrome and its components in a sample of the Tunisian population.

[136] Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and

[137] Sniderman AD, Kiss R. The strength and limitations of the apoB/apoA-I to predict the risk of vascular disease: a Hegelian analysis. Curr atheroscl rep. 2007; 9(4): 261-265. [138] Bruno G, Merletti F, Biggeri A, Bargero G, Prina-Cerai S, Pagano G, Cavallo-Perin P.

[139] Bayu M, Sasongo TY, Wong STY, Nguyen TT, Kawaskai R, Jenkins A, Shaw J, Wang JJ. Serum Apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than

subjects. Eur Heart J 2007; 28: 2637-2643. doi:10.1093/eurheartj/ehm360.

from a multi-ethnic US population. Eur Heart J. 2009; 30: 710-717.

Experimental and Molecular Pathology 2011; 91: 622-625.

traditional lipid. Diabetes Care 2011; 34: 474-479.

the metabolic syndrome. Curr Opin Lipidol 2007; 18: 633-637.

in male subjects with impaired fasting glucose. 2011; 21(8): 610-616.

Korean population. Int J Cardiol 2005; 101: 435-440.

Physicians India (JAPI) 2002; 50: 1036-1038.

ArteriosclerThromb Vasc Biol 2006; 26: 406-410.

Am J Cardiol 2004; 93: 159-164.

Diabetologia 2006; 49: 937-944.


Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia. Results from the ECLIPSE Study. Cardiology 2008; 111: 219-228. DOI: 10.1159/000127442.

[166] Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C for the ACCESS Study Group. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-highdensity lipoprotein cholesterol levels. Am J Cardiol 2001; 88: 265-269.

146 Lipoproteins – Role in Health and Diseases

1999; 23: 498-504.

Am Coll Cardiol 2008; 52: 293-299.

10.1161/STROKEAHA.110.595546.

Advance Access published July 9, 2011.

statins. Atherosclerosis 2011; 215: 1-218.

76.

2006; 111: 201-207. doi:10.1042/CS20060045 201.

[153] Smith J, Cianflone K, Al-Amri M, Sniderman A. Body composition and the apoB/apoA-I ratio in migrant Asian Indians and white Caucasians in Canada. Clin Sci

[154] Maffeis C, Pietrobelli A, Grezzani A, Provera S, Tato` L. Waist circumference and

[155] Gardner CD, Tribble DL, Young DR, Ahn D, Fortmann SP. Associations of HDL, HDL2, and HDL3 cholesterol and apolipoprotein A-I and B with lifestyle factors in healthy men and women: The Stanford Five City Project. Prev Med 2000; 30: 346-356. [156] Okosun IS, Prewitt TE, Liao Y, Cooper RS. Association of waist circumference with ApoB to ApoA-I ratio in black and white Americans. Int J Obes Relat Metab Disord

[157] Juonala M, Viikari JSA, Kähönen M, Solakivi T, Helenius H, Jula A, Marniemi J, Taittonen L, Laitinen T, Nikkari T, Raitakari OT. Childhood Levels of Serum Apolipoproteins B and A-I Predict Carotid Intima-Media Thickness and Brachial Endothelial Function in Adulthood The Cardiovascular Risk in Young Finns Study. J

[158] Mattsson N, Magnussen CG, Rönnemaa T, Mallat Z, Benessiano J, Jula A, Taittonen L, Kähönrn M, Juonala M, Viikari JSA,Raitakari OT. Metabolic Syndrome and Carotid Intima-Media Thickness in Young Adults: Roles of Apolipoprotein B, Apolipoprotein A-I, C-Reactive Protein, and Secretory Phospholipase A2: The Cardiovascular Risk in

[159] Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004; 35: 2248-2252. [160] Matsumoto K, Fujita N, Nakamura K, Senoo T, Tominaga T, Ueki Y. Apolipoprotein B and insulin resistance are good markers of carotid atherosclerosis in patients with type

[161] Kim SJ, Song P, Park JH, Lee YT, Kim WS, Park YG, Bang OY, Chung C-S, Lee KH, Kim G-M. Biomarkers of Asymptomatic Carotid Stenosis in Patients Undergoing Coronary Artery Bypass Grafting. Stroke 2011; 42: 734-739, DOI:

[162] Ajeganova S, Ehrnfelt C, Alizadeh R, Rohani M, Jogestrand T, Hafström I, Frostegård J. Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset—a prospective cohort study. Rheumatology 2011; 50: 1785-1793.

[163] Koha KK, Sakumab I, Quonc MJ. Review; Differential metabolic effects of distinct

[164] Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER). Am J Cardiol 2010; 105: 69-

[165] Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F on behalf of the ECLIPSE study investigators. Efficacy and Tolerability of Rosuvastatin and

Young Finns Study. Arterioscler Thromb Vasc Biol. 2010; 30: 1861-1866.

2 diabetes mellitus. Diabet Res Clin Pract 2008; 82: 93-97.

cardiovascular risk factors in prepubertal children. Obes Res 2001; 9: 179-87.

